For instance, patients with multiple-hit TP53 mutations and i(17q) presented with a particularly dismal outcome, which was consistent with previous studies reporting poor outcomes in TP53-mutated patients with other myeloid neoplasms, such as acute myeloid leukaemia and myelodysplastic syndromes19,25,31–33, and in CML-BC patients with i(17q)34–36. The gene discussed is TP53; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.